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Purpose or Objective: If radiotherapy (RT) combined with 
extended resection is part of the standard treatment of high 
risk extremity soft tissue sarcomas (ESTS), the evidence 
regarding the optimal target volume of RT ensuring local 
control (LC) is not very robust. But it is well known that 
toxicity is directly related to the RT volume and the 
delivered dose. The development of image-guided 
radiotherapy and implementation of better target volume 
conformation could reduce toxicity without compromising 
outcome. Here we evaluate the definition of RT volume 
according to clinical, surgical and histological factors. 
 
Material and Methods: Between the 1st January 2008 and the 
31th Decembre 2009, 173 patients from eleven centers with 
ESTS were retrospectively evaluated, all patients having had 
resection with pre- or post-operative RT. Primary endpoint 
was to evaluate the target volume and RT dose and their 
impact on LC and patterns of local relapse (LR). Secondary 
endpoints were: impact of surgery’s quality on LC, patterns 
of relapse and RT volume. Impact of RT dose on LC and 
patterns of LR. Impact of histological type on LC and on 
recurrent pattern. Impact of RT volume on toxicity (CTC 
V.04). 
 
Results: Median age was 60 years [19-91]. 32% of patients 
had upper limb and 68% lower limb STS. Median tumor size 
was 75mm [17-270]. RT was preoperative in 12% and 
postoperative in 88% of cases. Quality of surgery was R0 in 
62%; R0 after second surgery in 11% and R1 in 27% patients. 
Intraoperative tumor fragmentation rate was 6% in expert 
centers and 16% in non-expert centers. Most frequent 
histologic types were liposarcoma (31%) and 
myxofibrosarcoma (13%). Median dose was 54 Gy [36-70]. 
Median PTV1 and PTV2 volumes were 864cc [25-5122] and 
443cc [20-1613] respectively. LR rate was 11.20% (n=20); 45% 
within PTV1, 28% in the PTV2, 18% at the edge of the RT 
volume and 9% outside. 21.4% of patients had a metastatic 
failure. Regarding toxicity, we observed 19.6% and 15.2% of 
G1 and G2 fibrosis, 19.6% and 12.5% of G1 and G2 edema, 
12.6% and 4.5% G1 and G2 pain, 3.4% and 6.9% of G1 and G2 
joint stiffness, 5.2% and 6.9% G1 and G2 neuropathy. Bone 
fracture occurred in 3.2% of cases. After univariate analysis, 
intraoperative tumor fragmentation was related to a higher 
risk of LR (22% vs 8% p=0,004) and distant metastasis (50% vs 
17% p= 0,0029). Including scar drainage in the RT field was 
correlated to a lower LR rate (9% vs 29% p= 0,015). Upper 
limb location was correlated with higher risk of neuropathy 
(p=0,049) and lower limb location was correlated with edema 
(p=0,024). Dose > 60 Gy did not impact on LC but was 
correlated with pain (p=0,021). No significant correlation 
with fibrosis could be identified. 
 
Conclusion: As in other studies, the quality of surgery is the 
most important prognostic factor predicting outcome. Most of 
LR were within the PTV field translating a correct target 
volume definition. Toxicity was acceptable. A prospective 
evaluation is warranted. 
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Purpose or Objective: Radiotherapy remains the cornerstone 
of treatment for patients with DIPG. Nevertheless, median 
overall survival of patients initially responding to 
radiotherapy is poor. The role of chemotherapy as second-
line treatment remains elusive. Purpose of this study is to 
analyze the benefit and toxicity of re-irradiation at the time 
of disease progression. 
 
Material and Methods: At the time of disease progression 27 
children, aged 2 to 16, underwent re-irradiation (10 fractions 
of 1.8, 2.0 or 3.0 Gy) alone (N=21) or combined with systemic 
therapy (N=6). At first diagnosis, all patients had symptoms 
for ≤3 months, ≥2 signs of the neurological triad (cranial 
nerve deficit, ataxia, long tract signs), characteristic 
features of DIPG on magnetic resonance imaging or biopsy 
proven high-grade glioma. An interval of ≥3 months after 
first-line radiotherapy was required before re-irradiation. A 
group of 39 patients fulfilling the same diagnostic criteria 
receiving radiotherapy at primary diagnosis, followed by best 
supportive care (N=10) or systemic therapy (N=19), were 
eligible for a matched-cohort analysis. 
 
Results: Median overall survival for patients undergoing re-
irradiation was 15.9 months. For a similar median time to 
first progression (8.1 vs. 7.7 months; P=.22), a significant 
benefit in median overall survival (15.9 [95% CI 13.0-20.0] vs. 
10.3 [95% CI 9.4-12.5] months; P=<.01) was observed in favor 
of patients undergoing re-irradiation compared to no re-
irradiation. The median overall survival benefit of re-
irradiation versus no re-irradiation was most pronounced in 
patients with a longer interval between end-of-radiotherapy 
and first progression (3-6 months: 11.1 vs. 8.7; P=<.01; 6-12 
months: 19.4 vs. 13.8; P=.02). On multivariable analysis 
corrected for age and systemic therapy, re-irradiation 
remained prognostic for overall survival (HR 0.43 [0.13-81]; 
P=<.01). Clinical improvement after re-irradiation was 
observed in 15/20 (75%) patients. No grade 4 or 5 acute or 
late toxicity was diagnosed. 
 
Conclusion: The majority of patients with DIPG, responding 
to first-line radiotherapy, do benefit of re-irradiation. A 
prospective data collection, supported by the SIOP-E-
HGG/DIPG working group, will start for patients fulfilling the 
criteria of re-irradiation. 
 
PO-0770  
Subsequent colorectal adenomas in childhood cancer 
survivors: a DCOG LATER record linkage study 
J. Teepen
1Emma Children’s Hospital/Academic Medical Center, 
Pediatric Oncology, Amsterdam, The Netherlands 
1, J. Kok1, F. Van Leeuwen2,3, W. Tissing3,4, W. 
Dolsma3,5, H. Van der Pal3,6, E. Van Dulmen-den Broeder3,7, M. 
Van den Heuvel-Eibrink8,9, J. Loonen3,10, D. Bresters3,11, A. 
Versluys3,12, S. Neggers3,13, A. De Vries3,8, M. Jaspers3,14, M. 
Van den Berg3,7, H. Caron1,3, M. Van der Heiden-van der Loo3, 
N. Hollema3, DCOG LATER Study Group3, F. Oldenburger15, O. 
Visser16, L. Overbeek17, L. Kremer1,3, C. Ronckers1,3 
2Netherlands Cancer Institute, Epidemiology, Amsterdam, 
The Netherlands 
ESTRO 35  2016                                                                                                                                                  S361 
________________________________________________________________________________ 
3Stichting KinderOncologie Nederland SKION / Dutch 
Childhood Oncology Group DCOG, The Hague, The 
Netherlands 
4Beatrix Children's Hospital/University of 
Groningen/University Medical Center Groningen, Pediatric 
Oncology/Hematology, Groningen, The Netherlands 
5University of Groningen/University Medical Center 
Groningen, Radiation Oncology, Groningen, The Netherlands 
6Academic Medical Center, Medical Oncology, Amsterdam, 
The Netherlands 
7VU University Medical Center, Pediatric 
Oncology/Hematology, Amsterdam, The Netherlands 
8Sophia Children’s Hospital/Erasmus Medical Center, 
Pediatric Oncology/Hematology, Rotterdam, The 
Netherlands 
9Princess Maxima Center for Pediatric Oncology, Utrecht, 
The Netherlands 
10Radboud University Medical Center, Pediatric Oncology and 
Hematology, Nijmegen, The Netherlands 
11Willem-Alexander Children's Hospital/Leiden University 
Medical Center, Pediatric Stem Cell Transplantation, Leiden, 
The Netherlands 
12Wilhelmina Children's Hospital/University Medical Center 
Utrecht, Pediatric Oncology and Hematology, Utrecht, The 
Netherlands 
13Erasmus Medical Center, Internal Medicine, Rotterdam, The 
Netherlands 
14Academic Medical Center, Medical Informatics, Amsterdam, 
The Netherlands 
15Academic Medical Center, Radiation Oncology, Amsterdam, 
The Netherlands 
16Netherlands Comprehensive Cancer Organisation, 
Registration, Utrecht, The Netherlands 
17PALGA Foundation, Houten, The Netherlands 
 
Purpose or Objective: The risk of colorectal adenomas 
(CRAs) in childhood cancer survivors (CCS) is unknown. In the 
general population and in individuals with cancer 
susceptibility syndromes, CRAs are associated with colorectal 
carcinoma (CRC) risk and this knowledge is the basis for 
colorectal cancer screening. To support recommendations for 
or against CRC screening among asymptomatic CCS, we aim 
to estimate the risk of histologically confirmed CRAs in a 
large cohort of 5-year CCS and to quantify the contribution of 
associated treatment-related factors. 
 
Material and Methods: The Dutch Childhood Oncology Group-
Late Effects After Childhood Cancer (DCOG LATER) cohort 
includes 6,168 five-year CCS treated between 1/1/1963 and 
12/31/2001 in one of the seven Dutch pediatric 
oncology/hematology centers before age 18. Detailed 
information on prior cancer diagnosis and treatment was 
collected, including information on radiotherapy (RT) dose, 
field, and fractionation schedule and chemotherapy (CT) 
dose per drug. Subsequent CRAs were identified by linkage 
with the population-based Dutch Pathology Registry (PALGA) 
for follow-up years 1990-2014, a unique resource for case 
ascertainment without selection bias from self-reporting. 
Among patients with CRA we also ascertained the occurrence 
of CRC based on cancer registry linkage. 
 
Results: At a median follow-up of 23 years (range: 5-52) since 
childhood cancer diagnosis and a median attained age of 30 
years, we identified 60 patients with at least one 
histologically confirmed CRA, of which 37 had >1 CRA. Most 
common CRA histology was tubular adenoma, followed by 
tubulovillous adenoma. Median age at first CRA diagnosis was 
39 years and median time from childhood cancer diagnosis to 
CRA diagnosis was 28 years. Most CRA patients had been 
treated for leukemia (23.3%) or lymphomas (20.0%). Eight 
CRA patients also developed a CRC. Preliminary univariate 
analyses showed an increased risk of CRA associated with 
abdominal/pelvic RT (odds ratio=2.7; 95% CI: 1.5-4.9). 
 
Conclusion: This study shows a fairly high incidence of 
histologically confirmed CRAs in a relatively young 
population. However, these exploratory analyses need 
further in-depth medical file review to ascertain the 
potential for surveillance bias. More detailed analyses with 
multivariable risk models including RT dose and specific CT 
agents and the role of cancer susceptibility syndromes will be 
presented during the meeting. Also this study provides the 
baseline for a longitudinal assessment of CRA and CRC risk, as 
this population ages. 
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